Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, reported its financial results for the second quarter ending June 30, 2025. The company announced a net loss of $30.4 million for the period, compared to a net loss of $22.2 million in the same quarter of 2024. Research and development expenses saw an increase of $3.1 million, or 17.8%, totaling $20.8 million for the quarter. This rise was largely attributed to activities related to the company's MOLBREEVI program, including $3.3 million in costs related to Chemistry, Manufacturing, and Controls, and $1.1 million for Regulatory Affairs and Quality Assurance, partially offset by a $1.3 million reduction in clinical costs. Savara provided a business update indicating progress in their collaboration with Fujifilm as their drug substance manufacturer. Following a recent meeting with the FDA, Savara plans to resubmit the Biologics License Application $(BLA.AU)$ in December, with the finalization of the analytical data package expected early in the fourth quarter. The company is focused on addressing the unmet medical need for treating autoimmune PAP, a rare lung disease, with their MOLBREEVI program.